Inovio Pharmaceuticals, Inc. (INO:NASDAQ) closed at $1.04 on October 15, 2026, up 5.48% on the day. The stock trades 61.8% below its 52-week high of $2.72 and 85.7% above its 52-week low of $0.560. Over the past year, it lost 61.2%. Inovio Pharmaceuticals, Inc. is part of the Health Care sector (Medical/Dental Instruments).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -10.77% | -15.00% | -11.96% | -16.44% | -61.18% |
In 252 trading sessions since October 14, 2025, INO closed higher on 108 days (43%). Its best day was August 14, 2026 (+21.11%) and its worst was July 30, 2026 (-36.54%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceu...
Find more stocks like INO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.